Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Solventum (NYSE:SOLV - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 5.450-5.650 for the period, compared to the consensus earnings per share estimate of 5.540. The company issued revenue guidance of -.

Solventum Stock Performance

NYSE SOLV traded down $2.18 during trading hours on Monday, hitting $64.08. The company's stock had a trading volume of 786,324 shares, compared to its average volume of 1,320,199. The company's 50 day simple moving average is $73.41 and its two-hundred day simple moving average is $71.67. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The company has a market cap of $11.09 billion and a P/E ratio of 23.30. Solventum has a 12 month low of $47.16 and a 12 month high of $85.92.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a report on Monday, March 3rd. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a report on Friday, February 28th. Wells Fargo & Company boosted their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Solventum has an average rating of "Hold" and a consensus target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.